Publication

Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation.

Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, Wang Y, Xie S, Shen Y, Sang L, Zhang Z, Gao Z, Yang L, Qu L, Yang Z, He X, Guo Y, Pan C, Che J, Ju H, Liu J, Cai Z, Yan Q, Yu L, Wang L, Dong X, Xu P, Shao J, Liu Y, Li X, Wang W, Zhou R, Zhou T, Lin A

Immune checkpoint blockade therapies targeting the PD-L1/PD-1 axis have demonstrated clear clinical benefits. Improved understanding of the underlying regulatory mechanisms might contribute new insights into immunotherapy. Here, we identify transmembrane and ubiquitin-like domain-containing protein 1 (TMUB1) as a modulator of PD-L1 post-translational modifications in tumor cells. Mechanistically, TMUB1 competes with HECT, UBA and WWE domain-containing protein 1 (HUWE1), a E3 ... [more]

Throughput

• High Throughput

Related interactions

Curated By

• BioGRID